Angela is responsible for the development of unique end-to-end integrated evidence solutions for targeted clients founded on core market access capabilities. She is focused on creating a cohesive and integrated strategy for the market access consulting practice area by working in conjunction with Evidera and PPD teams to develop new client relationships, explore and develop new product offerings, and further develop the sales pipeline.
Most recently, Angela was executive director of PPD Consulting, where she led the strategic drug development consulting group. The group’s goal was to generate new client business for PPD, specifically aiming to form clinical development partnerships where PPD provides end-to-end programmatic support. She was also responsible for oversight of key client portfolios for sponsors with full product development programs. Angela has considerable experience within the pharmaceutical and biotech industry, leading strategic product development teams to major milestones, including global regulatory interactions, from preclinical stages through life-cycle management. She has a broad range of therapeutic experience, including oncology/hematology, immunology, diabetes, and infectious diseases. Angela established a strong background in corporate program management while at MedImmune-AstraZeneca and GlaxoSmithKline, where she led cross-functional product development teams in the oncology and inflammation therapeutic areas. During this tenure, she managed and co-led teams across all stages of pharmaceutical development (pre-clinical through post-marketing) for biologics and small molecule programs. Angela also spent two years outside of product development as a senior clinical scientist in oncology at MedImmune-AstraZeneca where she focused on expanding her experience in the clinical aspects of drug development. In that role, she was responsible for clinical development planning, synopsis and protocol development, KOL, investigator and site engagement, and clinical data review in solid tumour and hematologic malignancy programs.
Prior to her career in product development leadership and management, Angela worked as a bench scientist at both GlaxoSmithKline and Regeneron Pharmaceuticals where she focused on monoclonal antibody process development, optimization and research manufacturing. Angela earned a BS from North Carolina Agricultural & Technical State University, an MS in bio/chemical engineering from The Ohio State University, and an MBA from Saint Joseph’s University.